AAAAAA

   
Results: 1-9 |
Results: 9
SAFETY AND IMMUNOGENICITY OF A CANDIDATE THERAPEUTIC VACCINE, P24 VIRUS-LIKE PARTICLE, COMBINED WITH ZIDOVUDINE, IN ASYMPTOMATIC SUBJECTS
Authors: KELLEHER AD ROGGENSACK M JARAMILLO AB SMITH DE WALKER A GOW I MCMURCHIE M HARRIS J PATOU G COOPER DA
Citation: Ad. Kelleher et al., SAFETY AND IMMUNOGENICITY OF A CANDIDATE THERAPEUTIC VACCINE, P24 VIRUS-LIKE PARTICLE, COMBINED WITH ZIDOVUDINE, IN ASYMPTOMATIC SUBJECTS, AIDS, 12(2), 1998, pp. 175-182
EFFECTS OF IL-2 THERAPY IN ASYMPTOMATIC HIV-INFECTED INDIVIDUALS ON PROLIFERATIVE RESPONSES TO MITOGENS, RECALL ANTIGENS AND HIV-RELATED ANTIGENS
Authors: KELLEHER AD ROGGENSACK M EMERY S CARR A FRENCH MA COOPER DA
Citation: Ad. Kelleher et al., EFFECTS OF IL-2 THERAPY IN ASYMPTOMATIC HIV-INFECTED INDIVIDUALS ON PROLIFERATIVE RESPONSES TO MITOGENS, RECALL ANTIGENS AND HIV-RELATED ANTIGENS, Clinical and experimental immunology, 113(1), 1998, pp. 85-91
SAFETY AND IMMUNOGENICITY OF UBI HIV-1(MN) OCTAMERIC V3 PEPTIDE VACCINE ADMINISTERED BY SUBCUTANEOUS INJECTION
Authors: KELLEHER AD EMERY S CUNNINGHAM P DUNCOMBE C CARR A GOLDING H FORDE S HUDSON J ROGGENSACK M FORREST BD COOPER DA
Citation: Ad. Kelleher et al., SAFETY AND IMMUNOGENICITY OF UBI HIV-1(MN) OCTAMERIC V3 PEPTIDE VACCINE ADMINISTERED BY SUBCUTANEOUS INJECTION, AIDS research and human retroviruses, 13(1), 1997, pp. 29-32
IMMUNOLOGICAL EFFECTS OF ANTIRETROVIRAL AND IMMUNE THERAPIES FOR HIV
Authors: KELLEHER AD ALHARTHI L LANDAY AL
Citation: Ad. Kelleher et al., IMMUNOLOGICAL EFFECTS OF ANTIRETROVIRAL AND IMMUNE THERAPIES FOR HIV, AIDS, 11, 1997, pp. 149-155
CAN ANTIVIRAL THERAPY RESTORE IMMUNE FUNCTION
Authors: KELLEHER AD COOPER DA
Citation: Ad. Kelleher et Da. Cooper, CAN ANTIVIRAL THERAPY RESTORE IMMUNE FUNCTION, AIDS, 10, 1996, pp. 23-23
EFFECT OF THERAPEUTIC VACCINATION (P24-VLP) AND AZT ON IMMUNOLOGICAL MARKERS IN EARLY HIV DISEASE
Authors: KELLEHER AD SMITH DE COOPER DA WALKER A GOW I PATOU G
Citation: Ad. Kelleher et al., EFFECT OF THERAPEUTIC VACCINATION (P24-VLP) AND AZT ON IMMUNOLOGICAL MARKERS IN EARLY HIV DISEASE, AIDS, 10, 1996, pp. 137-137
STRATEGIES OF CARE IN MANAGING HIV
Authors: STEWART GJ IRVINE SS SCOTT M KELLEHER AD MARRIOTT DJE MCKNIGHT I PETHEBRIDGE AM WODAK A ZIEGLER J
Citation: Gj. Stewart et al., STRATEGIES OF CARE IN MANAGING HIV, Medical journal of Australia, 164(2), 1996, pp. 99-104
ALTERATIONS IN THE IMMUNE-RESPONSE OF HUMAN-IMMUNODEFICIENCY-VIRUS (HIV)-INFECTED SUBJECTS TREATED WITH AN HIV-SPECIFIC PROTEASE INHIBITOR,RITONAVIR
Authors: KELLEHER AD CARR A ZAUNDERS J COOPER DA
Citation: Ad. Kelleher et al., ALTERATIONS IN THE IMMUNE-RESPONSE OF HUMAN-IMMUNODEFICIENCY-VIRUS (HIV)-INFECTED SUBJECTS TREATED WITH AN HIV-SPECIFIC PROTEASE INHIBITOR,RITONAVIR, The Journal of infectious diseases, 173(2), 1996, pp. 321-329
INTRACTABLE HEADACHE AS THE PRESENTING COMPLAINT OF AIDS-RELATED LYMPHOMA CONFINED TO BONE
Authors: KELLEHER AD BREW BJ MILLIKEN ST
Citation: Ad. Kelleher et al., INTRACTABLE HEADACHE AS THE PRESENTING COMPLAINT OF AIDS-RELATED LYMPHOMA CONFINED TO BONE, Journal of acquired immune deficiency syndromes, 7(6), 1994, pp. 629-630
Risultati: 1-9 |